Glucosides

• 

  Subject Areas on Research

  • Acetylcholine receptor from Torpedo. Preferential solubilization and efficient reintegration into lipid vesicles. 
  • Biosynthesis of undecaprenyl phosphate-galactosamine and undecaprenyl phosphate-glucose in Francisella novicida. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. 
  • Characterization of acetylcholine receptor isolated from Torpedo californica electroplax through the use of an easily removable detergent, beta-D-octylglucopyranoside. 
  • Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). 
  • Cyanogenic glycosides and menisdaurin from Guazuma ulmifolia, Ostrya virgininana, Tiquilia plicata and Tiquilia canescens. 
  • Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. 
  • Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. 
  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 
  • Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. 
  • Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. 
  • Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? 
  • Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. 
  • Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. 
  • Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study). 
  • Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. 
  • Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. 
  • Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. 
  • Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. 
  • Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. 
  • Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. 
  • Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. 
  • Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. 
  • Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. 
  • Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. 
  • Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. 
  • Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. 
  • FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement? 
  • Fe(III) coordination properties of a new saccharide-based exocyclic trihydroxamate analogue of ferrichrome. 
  • Fe(III) coordination properties of two new saccharide-based enterobactin analogues: methyl 2,3,4-tris-O-[N-[2,3-di(hydroxy)benzoyl-glycyl]-aminopropyl]-alpha-D-glucopyranoside and methyl 2,3,4-tris-O-[N-[2,3-di-(hydroxy)-benzoyl]-aminopropyl]-alpha-D-glucopyranoside. 
  • From the editor: A run of success in treating atherosclerotic vascular disease. 
  • Functional expression of sodium-glucose transporters in cancer. 
  • Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. 
  • Good Guys, Bad Guys, Guesses, and Near Misses in Nephrology. 
  • In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status. 
  • Isolation and properties of beta-glucosidase from Ruminococcus albus. 
  • Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. 
  • Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. 
  • Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. 
  • Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. 
  • Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF". 
  • Specificity of C-glycoside complexation by mannose/glucose specific lectins. 
  • Structure of the water channel AqpZ from Escherichia coli revealed by electron crystallography. 
  • Synaptic vesicle membrane proteins interact to form a multimeric complex. 
  • The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition. 
  • The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. 
  • The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. 
  • The interaction of polyphenols with bilayers: conditions for increasing bilayer adhesion. 
  • The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 
  • Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. 
  • Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.